Comparative Analysis of Bispecific Antibody and Streptavidin-Targeted Radioimmunotherapy for B-cell Cancers
Streptavidin (SA)-biotin pretargeted radioimmunotherapy (PRIT) that targets CD20 in non-Hodgkin lymphoma (NHL) exhibits remarkable efficacy in model systems, but SA immunogenicity and interference by endogenous biotin may complicate clinical translation of this approach. In this study, we engineered...
Main Authors: | Green, Damian J., Frayo, Shani L., Lin, Yukang, Hamlin, Donald K., Fisher, Darrell R., Frost, Sofia H.L., Kenoyer, Aimee L., Hylarides, Mark D., Gopal, Ajay K., Gooley, Theodore A., Orozco, Johnnie J., Till, Brian G., O'Steen, Shyril, Orcutt, Kelly Davis, Wilbur, D. Scott, Wittrup, Karl Dane, Press, Oliver W. |
---|---|
Other Authors: | Massachusetts Institute of Technology. Department of Chemical Engineering |
Format: | Article |
Language: | English |
Published: |
American Association for Cancer Research (AACR)
2020
|
Online Access: | https://hdl.handle.net/1721.1/125642 |
Similar Items
-
Therapy of Myeloid Leukemia using Novel Bispecific Fusion Proteins Targeting CD45 and 90 Y-DOTA
by: Orozco, Johnnie J, et al.
Published: (2021) -
Effect of Small-Molecule-Binding Affinity on Tumor Uptake In Vivo: A Systematic Study Using a Pretargeted Bispecific Antibody
by: Rhoden, John J., et al.
Published: (2014) -
Radioimmunotherapy of lymphoma
by: Goldsmith Stanley J.
Published: (2012-01-01) -
Production of mutant streptavidin protein and investigation of its effect on the performance of streptavidin
by: Elham Didevara, et al.
Published: (2023-05-01) -
RADIOIMMUNOTHERAPY IN THE TREATMENT OF MALIGNANCIES
by: V. I. Chernov, et al.
Published: (2016-07-01)